Skip to main content
SpringerLink
Log in

Supportive Therapie des Melanoms

Supportive care for malignant melanoma

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

In der Therapie des malignen Melanoms werden verschiedenste Chemotherapien, Immuntherapien, Polychemotherapien und Immunochemotherapien angewandt. Zu diesen verschiedensten systemischen Therapien gehört eine optimale Begleittherapie, insbesondere in den Bereichen Nausea, Emesis, Prophylaxe und Therapie der Knochenmarksinsuffizienz, Fatigue und den kutanen Nebenwirkungen. Die spezifisch dermatoonkologischen Begleittherapien werden detailliert beschrieben.

Abstract

In the systemic therapy of malignant melanoma, many forms of chemotherapy, immunotherapy, polychemotherapy and immunopolychemotherapy are being use. When administering such forms of therapy, optimal supportive care is essential. Important aspects include control of nausea and vomiting, prophylaxis and treatment of bone marrow failure, reducing fatigue and being alert to cutaneous side effects. Specific recommendations for all of these dermato-oncologic problems are provided in detail.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Berger AM et al. (2001) Principles and practice of oncology. Cancer. Lippincott, Philadelphia, pp 2869–2880

  2. Hesketh PJ (1999) Defining the emetogenicity of cancer chemotherapy regimes: relevance to clinical practice. Oncologist 4: 191–196

    PubMed  CAS  Google Scholar 

  3. Grundberg S et al. (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100: 2261–2268

    Article  Google Scholar 

  4. Hichok JT, Roscoe JA, Morrow GR (2001) The role of patients‘ expectations in the development of anticipatory nausea related to chemotherapy for cancer. J Pain Symptom Manage 22(4): 843–850

    Article  Google Scholar 

  5. Kris M, Hesketh P, Somerfiel M et al. (2006) American Society of Clinical Oncology guideline for antiemetics in oncology. J Clin Oncol 24: 2932–2947

    Article  PubMed  CAS  Google Scholar 

  6. National Comprehensive Cancer Network (2007) Antiemesis. NCCN Clinical Practice Guidelines in Oncology (available at http://www.cnnc.org)

  7. Roila R, Hesketh PJ, Herrstedt J et al. (2006) Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17: 20–28

    Article  PubMed  CAS  Google Scholar 

  8. Bokemeyer C, Aapro MS, Courdi A et al. (2004) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40(15): 2201–2216

    Article  PubMed  CAS  Google Scholar 

  9. Rizzo JD, Somerfiel MR, Hagerty KI et al. (2008) Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update. J Clin Oncol 26: 132–149

    Article  PubMed  CAS  Google Scholar 

  10. Aapro MS, Cameron DA, Pettengell R et al. (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patientes with lymphomas and solid tumours. Eur J Cancer 42: 2433–2453

    Article  PubMed  CAS  Google Scholar 

  11. Smith TJ, Khatcheressian J, Lyman GH et al. (2006) Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24(19): 3187–3205

    Article  PubMed  CAS  Google Scholar 

  12. Loge JH, Abrahamsen AF, Ekeberg O et al. (1999) Hodgkin’s disease survivors have more fatigue than the general population. J Clin Oncol 17: 253–261

    PubMed  CAS  Google Scholar 

  13. Visser MR, Smets EM (1998) Fatigue, depression and quality of life in cancer patients: how are they related? Support Care Cancer 6: 101–108

    Article  PubMed  CAS  Google Scholar 

  14. Blockmans DM, Persoons P, Van Houdenhove B et al. (2006) Does methylphenidate reduce the symptoms of chronic fatigue syndrome? Am J Med 119(2): 167.e23–30

    Article  PubMed  Google Scholar 

  15. Mader I, Fürst-Weger P, Nogler-Semenitz E et al. (2002) Paravasation von Zytostatika, Springer, Wien

  16. Schmoll HJ, Höffken K, Possinger K et al. (2006) Kompendium Internistische Onkologie, 4. Aufl. Springer, Berlin Heidelberg New York Tokyo

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Elbeklinikum Buxtehude, Am Krankenhaus 1, 21614, Buxtehude, Deutschland

    P. Mohr

Authors
  1. P. Mohr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Mohr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mohr, P. Supportive Therapie des Melanoms. Hautarzt 59, 492–498 (2008). https://doi.org/10.1007/s00105-008-1564-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-008-1564-5

Schlüsselwörter

Keywords

Search

Navigation